Asset Details
Do you wish to reserve the book?
Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model
Do you wish to request the book?
Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model
2024
Overview
Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine have limited effectiveness in eliminating the infection and were linked to a variety of adverse effects. Therefore, the search for new effective therapeutic strategies against toxoplasmosis is still required. The current work is the first research to assess the efficacy of spiramycin-loaded maltodextrin nanoparticles (SPM-loaded MNPs) as a novel alternative drug therapy against toxoplasmosis in a murine model. Fifty laboratory-bred Swiss albino mice were divided into five groups: normal control group (GI,
n
= 10), positive control group (GII,
n
= 10), orally treated with spiramycin (SPM) alone (GIII,
n
= 10), intranasal treated with SPM-loaded MNPs (GIV,
n
= 10), and orally treated with SPM-loaded MNPs (GV,
n
= 10). Cysts of
Toxoplasma gondii
ME-49 strain were used to infect the mice. Tested drugs were administered 2 months after the infection. Drug efficacy was assessed by counting brain cysts, histopathological examination, and measures of serum CD19 by flow cytometer. The orally treated group with SPM-loaded MNPs (GV) showed a marked reduction of brain cyst count (88.7%), histopathological improvement changes, and an increasing mean level of CD19 (80.2%) with significant differences. SPM-loaded MNPs showed potent therapeutic effects against chronic toxoplasmosis. Further research should be conducted to assess it in the treatment of human toxoplasmosis, especially during pregnancy.
Graphical Abstract
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Animals
/ Antiprotozoal Agents - administration & dosage
/ Antiprotozoal Agents - therapeutic use
/ Biomedical and Life Sciences
/ brain
/ Cysts
/ Dextrins
/ Female
/ Fetuses
/ humans
/ Liver
/ Mice
/ Polysaccharides - administration & dosage
/ Polysaccharides - pharmacology
/ Polysaccharides - therapeutic use
/ Protozoa
/ Spiramycin - administration & dosage
/ Spiramycin - therapeutic use
/ Spleen
/ Tissues
/ Toxicity
/ Toxoplasmosis - drug therapy
We currently cannot retrieve any items related to this title. Kindly check back at a later time.